• Skip to primary navigation
  • Skip to main content
Neural Stem Cell Institute, Rensselaer NY

Neural Stem Cell Institute, Rensselaer NY

Stem cell research and applications in the treatment of diseases like Retinitis Pigmentosis, Alzheimer's, Parkinson's, Spinal Cord Injury, Retinal Degeneration. Home of SallyTemple's lab.

  • Home
  • Support NSCI
  • Research
    • Alzheimer’s Program
    • Retinal Disease: Age-Related Macular Degeneration
    • Parkinson’s Disease Program
    • Spinal Cord Injury Program
    • Computing @ NSCI
  • NeuraCell
  • Tau Consortium
  • News
  • About Us
    • Our Team
  • Contact Us
    • Careers
    • Volunteer Internship
    • Collaboration Inquiries
    • Media Inquiries
  • Show Search
Hide Search

NSCI IND Allowance for AMD Clinical Trial

Sally Temple · April 2, 2021 · Leave a Comment

Promise for patients with Age-Related Macular Degeneration

NSCI is pleased to announce our successful IND application to the FDA that will enable clinical testing of a novel stem cell therapy for patients with age-related macular degeneration (AMD).

In AMD, the retinal pigment epithelial cells (RPE) at the back of the eye degenerate, causing loss of vision. Patients with AMD lose the ability to read and recognize faces, which is debilitating and isolating. 1 in 5 people over age 75 develop AMD, and there is great need to develop new therapies to slow or prevent disease progress. Dr. Jeffrey Stern and team at NSCI discovered an adult stem cell present in the RPE layer that can be used to provide new RPE cells to replace those lost to disease. Dr. Stern’s team have performed careful tests in animals that indicate safety and efficacy, and have manufactured clinical grade RPE cells. Now they have been given the green light to move to clinical testing in subjects with AMD. Plans to start the clinical trial have commensed at the University of Michigan Kellogg Eye Center, with the study lead Dr. Rajesh Rao. The clinical trial is being supported by the National Eye Institute (NEI) and Luxa Biotech and the NIH Regenerative Innovation Project (RMIP).

Current News age-related macular degeneration, clinical trial, neural stem cell institute, retinal pigment epithelial cell, stem cell

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Neural Stem Cell Institute, Rensselaer NY

Copyright © 2025 - This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

  • Home
  • Support NSCI
  • Research
  • NeuraCell
  • Tau Consortium
  • News
  • About Us
  • Contact Us